{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:09:37Z","timestamp":1790845777969,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Health Labor Sciences Research Grant from the Ministry of Health, Labor, and Welfare of Japan","award":["19EA1010"],"award-info":[{"award-number":["19EA1010"]}]},{"name":"the NIHR Manchester Biomedical Centre"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Stereotactic body radiotherapy (SBRT) is a promising approach in treating painful bone metastases. However, the superiority of SBRT over conventional external beam radiotherapy (cEBRT) remains controversial. Therefore, this systematic review and meta-analysis of randomised controlled trials was conducted to compare SBRT and cEBRT for the treatment of bone metastases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A search was conducted using PubMed on January 22, 2022, with the following inclusion criteria: (i) randomised controlled trials comparing SBRT with cEBRT for bone metastases and (ii) endpoint including pain response. Effect sizes across studies were pooled using random-effects models in a meta-analysis of risk ratios.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 1246 articles were screened, with 7 articles comprising 964 patients (522 and 442 patients in the SBRT and cEBRT arms, respectively) meeting the inclusion criteria. The overall pain response (OR) rates of bone metastases at 3\u00a0months were 45% and 36% in the SBRT and cEBRT arms, respectively. The present analyses showed no significant difference between the two groups. In four studies included for the calculation of OR rates of spinal metastases at three months, the OR rates were 40% and 35% in the SBRT and cEBRT arms, respectively, with no significant difference between the two groups. The incidence of severe adverse effects and health-related quality of life outcomes were comparable between the two arms.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The superiority of SBRT over cEBRT for pain palliation in bone metastases was not confirmed in this meta-analysis. Although SBRT is a standard of care for bone metastases, patients receiving SBRT should be selected appropriately.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-022-02128-w","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T16:03:23Z","timestamp":1663085003000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Stereotactic body radiotherapy versus conventional radiotherapy for painful bone metastases: a systematic review and meta-analysis of randomised controlled trials"],"prefix":"10.1186","volume":"17","author":[{"given":"Kei","family":"Ito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuki","family":"Imano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hoskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,13]]},"reference":[{"key":"2128_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.prro.2016.08.001","volume":"7","author":"S Lutz","year":"2017","unstructured":"Lutz S, Balboni T, Jones J, Lo S, Petit J, Rich SE, et al. Palliative radiation therapy for bone metastases: update of an ASTRO evidence-based guideline. Pract Radiat Oncol. 2017;7:4\u201312. https:\/\/doi.org\/10.1016\/j.prro.2016.08.001.","journal-title":"Pract Radiat Oncol"},{"key":"2128_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1515\/fco-2015-0007","volume":"6","author":"AH Anter","year":"2015","unstructured":"Anter AH. Single fraction versus multiple fraction radiotherapy for treatment of painful bone metastases: a prospective study; Mansoura experience. Forum Clin Oncol. 2015;6:8\u201313. https:\/\/doi.org\/10.1515\/fco-2015-0007.","journal-title":"Forum Clin Oncol"},{"key":"2128_CR3","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.radonc.2018.01.003","volume":"126","author":"SE Rich","year":"2018","unstructured":"Rich SE, Chow R, Raman S, Zeng KL, Lutz S, Lam H, et al. Update of the systematic review of palliative radiation therapy fractionation for bone metastases. Radiother Oncol. 2018;126:547\u201357. https:\/\/doi.org\/10.1016\/j.radonc.2018.01.003.","journal-title":"Radiother Oncol"},{"key":"2128_CR4","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.clon.2011.11.004","volume":"24","author":"E Chow","year":"2012","unstructured":"Chow E, Zeng L, Salvo N, Dennis K, Tsao M, Luts S. Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol (R Coll Radiol). 2012;24:112\u201324. https:\/\/doi.org\/10.1016\/j.clon.2011.11.004.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2128_CR5","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ijrobp.2019.07.009","volume":"105","author":"K Spencer","year":"2019","unstructured":"Spencer K, Velikova G, Henry A, Westhoff P, Hall PT, van der Lindan YM. Net pain relief after palliative radiation therapy for painful bone metastases: a useful measure to reflect response duration? A further analysis of the Dutch bone metastasis study. Int J Radial Oncol Biol Phys. 2019;105:559\u201366. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.07.009.","journal-title":"Int J Radial Oncol Biol Phys"},{"key":"2128_CR6","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.clon.2012.04.006","volume":"24","author":"A Sahgal","year":"2012","unstructured":"Sahgal A, Roberge D, Schellenberg D, Purdie TG, Swaminath A, Pantarotto J, et al. The Canadian Association of Radiation Oncology scope of practice guidelines for lung, liver and spine stereotactic body radiotherapy. Clin Oncol (R Coll Radiol). 2012;24:629\u201339. https:\/\/doi.org\/10.1016\/j.clon.2012.04.006.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2128_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/01.brs.0000251863.76595.a2","volume":"32","author":"PC Gerszten","year":"2007","unstructured":"Gerszten PC, Burton SA, Ozhasoglu C, Welch WC. Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution. Spine (Phila Pa 1976). 2007;32:193\u20139. https:\/\/doi.org\/10.1097\/01.brs.0000251863.76595.a2.","journal-title":"Spine (Phila Pa 1976)"},{"key":"2128_CR8","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.ijrobp.2.020.12.045","volume":"110","author":"M Guckenberger","year":"2021","unstructured":"Guckenberger M, Mantel F, Sweeney RA, Hawkins M, Belderbos J, Ahmed M, et al. Long-term results of dose-intensified fractionated stereotactic body radiation therapy (SBRT) for painful spinal metastases. Int J Radiat Oncol Biol Phys. 2021;110:348\u201357. https:\/\/doi.org\/10.1016\/j.ijrobp.2.020.12.045.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2128_CR9","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3171\/2017.1.SPINE16684","volume":"27","author":"ZA Husain","year":"2017","unstructured":"Husain ZA, Sahgal A, De Salles A, Funaro M, Glover J, Hayashi M, et al. Stereotactic body radiotherapy for de novo spinal metastases: systematic review. J Neurosurg Spine. 2017;27:295\u2013302. https:\/\/doi.org\/10.3171\/2017.1.SPINE16684.","journal-title":"J Neurosurg Spine"},{"key":"2128_CR10","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.ijrobp.2019.06.382","volume":"105","author":"S Ryu","year":"2019","unstructured":"Ryu S, Deshmukh S, Timmerman RD, Movsas P, Gerztan PC, Yin FF, et al. Radiosurgery compared to external beam radiotherapy for localized spine metastasis: phase III results of NRG Oncology\/RTOG 0631. Int J Radiat Oncol Biol Phys. 2019;105:S2-3. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.06.382.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2128_CR11","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1470-2045(21)00196-0","volume":"22","author":"A Sahgal","year":"2021","unstructured":"Sahgal A, Myrehaug SD, Siva S, Masucci GL, Maralani PJ, Brundage M, et al. Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2\/3 trial. Lancet Oncol. 2021;22:1023\u201333. https:\/\/doi.org\/10.1016\/S1470-2045(21)00196-0.","journal-title":"Lancet Oncol"},{"key":"2128_CR12","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.rec.2021.07.010","volume":"74","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutrann I, Hoffman TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Esp Cardiol (Engl Ed). 2021;74:790\u20139. https:\/\/doi.org\/10.1016\/j.rec.2021.07.010.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2128_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"2128_CR14","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ"},{"key":"2128_CR15","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1001\/jamaoncol.2019.0192","volume":"5","author":"QN Nguyen","year":"2019","unstructured":"Nguyen QN, Chun SG, Chow E, Komaki R, Lia Z, Zacharia R, et al. Single-fraction stereotactic vs conventional multifraction radiotherapy for pain relief in patients with predominantly nonspine bone metastases: a randomized phase 2 trial. JAMA Oncol. 2019;5:872\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0192.","journal-title":"JAMA Oncol"},{"key":"2128_CR16","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.radonc.2015.04.022","volume":"115","author":"D Berwouts","year":"2015","unstructured":"Berwouts D, De Wolf K, Lambert B, Bultijnck R, De Neve W, De Lobel L, et al. Biological 18[F]-FDG-PET image-guided dose painting by numbers for painful uncomplicated bone metastases: a 3-arm randomized phase II trial. Radiother Oncol. 2015;115:272\u20138. https:\/\/doi.org\/10.1016\/j.radonc.2015.04.022.","journal-title":"Radiother Oncol"},{"key":"2128_CR17","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.31557\/APJCP.2020.21.6.1807","volume":"21","author":"A Sakr","year":"2020","unstructured":"Sakr A, Hashem WB, Ebrahim N, Mashhour KN. Randomized pilot study of 20 Gy in 5 fractions versus 27 Gy in 3 fractions radiotherapy for treating painful bone metastases: a single institution experience. Asian Pac J Cancer Prev. 2020;21:1807\u201311. https:\/\/doi.org\/10.31557\/APJCP.2020.21.6.1807.","journal-title":"Asian Pac J Cancer Prev"},{"key":"2128_CR18","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.ijrobp.2020.11.060","volume":"110","author":"BJ Pielkenrood","year":"2021","unstructured":"Pielkenrood BJ, van der Velden JM, van der Linden YM, Bartels MMT, Kasperts N, Verhoeff JJC, et al. Pain response after stereotactic body radiation therapy versus conventional radiation therapy in patients with bone metastases-a phase 2 randomized controlled trial within a prospective cohort. Int J Radiat Oncol Biol Phys. 2021;110:358\u201367. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.11.060.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2128_CR19","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.radonc.2018.04.030","volume":"128","author":"T Sprave","year":"2018","unstructured":"Sprave T, Verma V, F\u00f6rster R, Schlampp I, Bruckner T, Bostel T, et al. Randomized phase II trial evaluating pain response in patients with spinal metastases following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy. Radiother Oncol. 2018;128:274\u201382. https:\/\/doi.org\/10.1016\/j.radonc.2018.04.030.","journal-title":"Radiother Oncol"},{"key":"2128_CR20","unstructured":"Radiation Therapy Oncology Group. Image-guided radiosurgery or stereotactic body radiation therapy in treating patients with localized spine metastasis, https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00922974?view=results; 2021. Accessed 30 Jan 2022]."},{"key":"2128_CR21","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1016\/j.ijrobp.2011.02.008","volume":"82","author":"E Chow","year":"2012","unstructured":"Chow E, Hoskin P, Mitera G, Zeng L, Lutz S, Roos D, et al. Update of the international consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Int J Radiat Oncol Biol Phys. 2012;82:1730\u20137. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.02.008.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2128_CR22","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.ijrobp.2021.12.163","volume":"112","author":"BJ Pielkenrood","year":"2022","unstructured":"Pielkenrood BJ, Gal R, Kasperts N, Verhoeff JJC, Bartels MMTJ, Seravalli E, et al. Quality of life after stereotactic body radiation therapy versus conventional radiation therapy in patients with bone metastases. Int J Radiat Oncol Biol Phys. 2022;112:1203\u201315. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.12.163.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2128_CR23","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.21873\/anticanres.12814","volume":"38","author":"T Sprave","year":"2018","unstructured":"Sprave T, Verma V, F\u00f6rster R, Schlampp I, Bruckner T, Bostel T, et al. Quality of life following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy for vertebral metastases: secondary analysis of an exploratory phase II randomized trial. Anticancer Res. 2018;38:4961\u20138. https:\/\/doi.org\/10.21873\/anticanres.12814.","journal-title":"Anticancer Res"},{"key":"2128_CR24","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.rpor.2019.12.018","volume":"25","author":"K Ito","year":"2020","unstructured":"Ito K, Nakamura N, Shimizuguchi T, Ogawa H, Karasawa K. Appropriate endpoints for stereotactic body radiotherapy for bone metastasis: classification into five treatment groups. Rep Pract Oncol Radiother. 2020;25:150\u20133. https:\/\/doi.org\/10.1016\/j.rpor.2019.12.018.","journal-title":"Rep Pract Oncol Radiother"},{"key":"2128_CR25","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ijrobp.2011.12.039","volume":"84","author":"W Li","year":"2012","unstructured":"Li W, Sahgal A, Foote M, Millar BA, Jaffray DA, Letourneau D. Impact of immobilization on intrafraction motion for spine stereotactic body radiotherapy using cone beam computed tomography. Int J Radiat Oncol Biol Phys. 2012;84:520\u20136. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.12.039.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2128_CR26","doi-asserted-by":"publisher","first-page":"e595","DOI":"10.1016\/S1470-2045(15)00166-7","volume":"16","author":"I Thibault","year":"2015","unstructured":"Thibault I, Chang EL, Sheehan J, Ahluwalia MS, Guckenberger M, Sohn MJ, et al. Response assessment after stereotactic body radiotherapy for spinal metastasis: a report from the SPIne response assessment in Neuro-Oncology (SPINO) group. Lancet Oncol. 2015;16:e595-603. https:\/\/doi.org\/10.1016\/S1470-2045(15)00166-7.","journal-title":"Lancet Oncol"},{"key":"2128_CR27","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ijrobp.2015.04.050","volume":"93","author":"C Tang","year":"2015","unstructured":"Tang C, Hess K, Bishop AJ, Pan HY, Christensen EN, Yang JN, et al. Creation of a prognostic index for spine metastasis to stratify survival in patients treated with spinal stereotactic radiosurgery: secondary analysis of mature prospective trials. Int J Radiat Oncol Biol Phys. 2015;93:118\u201325. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.04.050.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2128_CR28","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1093\/neuros\/nyx493","volume":"83","author":"S Faruqi","year":"2018","unstructured":"Faruqi S, Tseng CL, Whyne C, Alghamdi M, Wilson J, Myrehaug S, et al. Vertebral compression fracture after spine stereotactic body radiation therapy: a review of the pathophysiology and risk factors. Neurosurgery. 2018;83:314\u201322. https:\/\/doi.org\/10.1093\/neuros\/nyx493.","journal-title":"Neurosurgery"},{"key":"2128_CR29","doi-asserted-by":"publisher","first-page":"00723","DOI":"10.1016\/j.ijrobp.2022.07.003","volume":"S0360\u20133016","author":"I Madani","year":"2022","unstructured":"Madani I, Sahgal A, Erler D, Stish BJ, Olivier KR, Park SS, et al. Stereotactic body Radiation therapy for metastases in long bones. Int J Radiat Oncol Biol Phys. 2022;S0360\u20133016:00723\u20134. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.07.003.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2128_CR30","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.radonc.2018.03.030","volume":"127","author":"D Erler","year":"2018","unstructured":"Erler D, Brotherston D, Sahgal A, Cheung P, Loblaw A, Chu W, et al. Local control and fracture risk following stereotactic body radiation therapy for non-spine bone metastases. Radiother Oncol. 2018;127:304\u20139. https:\/\/doi.org\/10.1016\/j.radonc.2018.03.030.","journal-title":"Radiother Oncol"},{"key":"2128_CR31","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/s0360-3016(98)00288-0","volume":"42","author":"H Katagiri","year":"1998","unstructured":"Katagiri H, Takahashi M, Inagaki J, Koyabashi H, Sugiura H, Yamamura S, et al. Clinical results of nonsurgical treatment for spinal metastases. Int J Radiat Oncol Biol Phys. 1998;42:1127\u201332. https:\/\/doi.org\/10.1016\/s0360-3016(98)00288-0.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2128_CR32","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S1470-2045(13)70556-4","volume":"15","author":"E Chow","year":"2014","unstructured":"Chow E, van der Linden YM, Roos D, Hartsell WF, Hoskin P, Wu JSY, et al. Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial. Lancet Oncol. 2014;15:164\u201371. https:\/\/doi.org\/10.1016\/S1470-2045(13)70556-4.","journal-title":"Lancet Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-022-02128-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-022-02128-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-022-02128-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T16:03:42Z","timestamp":1663085022000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-022-02128-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,13]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2128"],"URL":"https:\/\/doi.org\/10.1186\/s13014-022-02128-w","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,13]]},"assertion":[{"value":"24 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the institutional ethical review board of Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital (approval number: 2844).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"156"}}